Phase 1 trial of PMC-403 introduces multi-dose cohort


The pharmaceutical candidate is being evaluated as a potential treat for nAMD.

Image credit: AdobeStock/AIExplosion

(Image credit: AdobeStock/AIExplosion)

PharmAbcine, Inc. has decided to advance the treatment candidate, PMC-403 to a fourth single-dose group of 4 mg and a first multiple-dose group of 3 mg in Phase 1 clinical trial. PMC-403 is being evaluated for the treatment of neovascular age-related macular degeneration (nAMD).1

According to the press release1, the candidate is a TIE2-activating antibody with the mechanism of stabilizing pathological and leaky blood vessels. TIE2 receptors, expressed on endothelial cells, are involved in vessel normalization processes such as angiogenesis and intercellular adhesion.

The current phase 1 trial is targeting patients with nAMD who are not responding to anti-VEGF standard therapeutics.1

Dr Weon Sup Lee, Head of R&D and Chief Technology Officer at PharmAbcine, shared the hope for this drug’s potential as an AMD treatment in the press release1, saying, "Despite standard anti-VEGF treatments, many patients with neovascular age-related macular degeneration continue to experience vision loss and retinal vascular leakage. We are committed to delivering an innovative new drug with differentiated mode of action for these patients. If final safety is confirmed in this Phase 1 trial, the likelihood of advancing to Phase 2 will increase, paving the way for the commercialization of this treatment."

These phase 1 trials for the treatment of nAMD are being conducted in Korea.1

1. PharmAbcine's Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg. PharmAbcine. Published July 2, 2024. Accessed July 2, 2024.
Related Videos
Marion Munk, MD, PhD, presenting slides
Marion Munk, MD, PhD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.